🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ULBI ULBI

Company Profile ↓
$5.31
-31.31% 1Y
Mkt Cap$112.00M
P/E-15.17
P/B0.86
52W High$8.23
52W Low$5.05
Book Value$6.16
EPS (TTM)$-0.35

Company Overview

ULBI (ULBI) is a publicly traded company listed on with a market capitalization of $112.00M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.38.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $191.16M (+16.2% YoY); net profit $-5.90M.
  • Trailing 12 Months Year-on-year growth — revenue +16.2%, earnings -193.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.44%
1 Year:16.24%

Compounded Profit Growth

5 Years:-
1 Year:-193.44%

Stock Price Performance

1 Year:-31.31%
6 Months:-19.42%
3 Months:-22.25%
1 Month:-11.20%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 8% of range
$5.05 $8.23
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)39.75 · Neutral
Price Performance
1M-11.20%
3M-22.25%
6M-19.42%
1Y-31.31%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Trading 35.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-15.17
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$6.16
Price to Book
0.86
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
1.44%
Profit 5Y
-
Revenue (YoY)
16.24%
Earnings (YoY)
-193.44%

Profitability & Returns

ROCE
3.50%
ROE
-4.54%
ROA
-2.72%
Profit Margin
-3.09%
Op Margin
3.28%
Gross Margin
24.07%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-0.35

Balance Sheet & Liquidity

Debt/Equity
0.38
Quick Ratio
1.39
Current Ratio
2.83
Debt
$49.65M
Total Assets
$220.63M
Current Assets
$110.10M
Working Capital
$68.47M

Ownership

Promoter Holding
3.22%
Chg in Prom Hold
-
FII / Inst Holding
74.26%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$191.16M
EBITDA
$1.05M
Free Cash Flow
$7.12M
Operating Cash Flow
$10.99M
Shares Outstanding
21.09M
Gross Margin
24.07%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Apr 2017Jul 2017Oct 2017Apr 2018Jul 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 17.28M20.36M15.29M15.20M16.06M19.18M18.95M19.04M20.83M20.37M19.63M22.04M19.94M21.05M------25.81M--25.97M26.77M21.76M30.37M32.13M33.23M31.92M42.69M39.49M41.93M42.98M35.69M50.75M48.56M43.37M48.48M47.45M
Cost of Revenue -----------------------------------38.00M36.96M33.75M36.42M37.34M
Gross Profit 4.52M6.13M4.33M4.21M4.49M6.01M5.86M5.90M6.41M5.90M6.00M6.89M6.22M6.25M7.28M6.55M6.04M5.08M8.87M7.86M7.33M7.96M6.51M6.98M7.27M5.11M6.96M7.65M6.71M7.44M10.59M9.77M11.47M11.56M8.68M12.74M11.60M9.62M12.06M10.11M
Operating Expenses -----------------------------------9.35M9.35M10.57M10.48M10.32M
Operating Income -1.87M652.00K-1.10M-1.32M-55.00K822.00K817.00K1.17M482.00K499.00K1.14M1.84M1.32M1.26M2.36M1.63M1.50M548.00K3.04M1.31M1.49M2.29M707.00K952.00K1.09M-779.00K-295.00K793.00K-586.00K26.00K3.67M2.13M4.06M3.92M511.00K3.40M2.26M-951.00K1.57M-215.00K
EBITDA -----------------------------------4.83M3.52M660.00K-7.96M1.53M
Interest Expense -----------------------------------1.03M992.00K992.00K937.00K868.00K
Pretax Income -----------------------------------2.45M1.11M-1.75M-10.21M-663.00K
Tax Provision -----------------------------------567.00K243.00K-504.00K-2.75M-192.00K
Net Income -2.07M644.00K-1.29M-1.36M-323.00K533.00K788.00K1.05M299.00K446.00K1.02M1.66M1.09M1.10M2.15M1.63M1.41M425.00K2.26M898.00K1.06M1.66M407.00K671.00K811.00K-585.00K-168.00K512.00K-239.00K-346.00K3.34M1.33M2.89M2.97M258.00K1.86M879.00K-1.22M-7.42M-451.00K
Diluted EPS -0.120.04--0.08-0.030.050.070.020.030.070.110.070.070.130.100.090.0314.006.007.0010.003.004.000.050.05-0.010.030.030.030.030.080.080.180.020.110.05-0.07-0.45-0.03
R&D Expense 1.67M1.42M1.44M1.56M1.01M1.36M1.33M1.22M1.66M1.43M1.36M1.14M1.19M1.35M1.10M1.22M1.10M1.04M1.59M2.03M1.55M1.27M1.61M1.65M1.85M1.72M1.86M1.67M1.90M2.03M1.78M1.87M1.76M2.00M2.10M2.40M2.32M2.85M-2.96M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 154.29M166.82M135.74M101.66M78.83M66.49M76.43M82.46M85.53M87.19M106.80M107.71M-131.84M158.64M164.46M191.16M
Cost of Revenue -------------102.44M119.44M122.14M145.14M
Gross Profit 35.31M46.66M34.19M28.73M22.62M19.35M23.32M25.11M26.23M25.58M31.16M29.16M-29.40M39.20M42.31M46.02M
Operating Expenses -------------29.27M29.73M32.35M39.74M
Operating Income -3.55M11.86M2.41M-114.00K-624.00K-1.44M3.33M3.76M6.48M6.55M7.37M5.70M-129.00K9.47M9.96M6.28M
EBITDA -------------4.96M15.04M14.40M1.05M
Interest Expense -------------951.00K2.02M1.94M3.95M
Pretax Income --------------446.00K9.12M8.30M-8.40M
Tax Provision --------------326.00K1.95M1.89M-2.45M
Net Income -9.24M-6.18M-2.08M-1.60M-926.00K-2.12M2.87M3.51M7.65M24.93M5.21M5.23M--119.00K7.20M6.31M-5.90M
Diluted EPS -0.54-0.36-0.12-0.09-0.05-0.170.230.481.5332.000.33--0.010.440.38-0.35
R&D Expense 9.45M8.76M8.59M7.22M5.86M5.33M5.60M5.95M4.74M4.51M6.80M5.95M6.83M7.08M7.53M8.27M10.40M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --114.83M100.81M97.72M90.19M87.64M81.52M84.74M97.19M120.85M144.56M137.70M-168.43M178.28M220.45M216.91M
Current Assets --------------78.99M90.20M97.16M105.80M
Cash & Equivalents 1.88M6.09M4.64M5.32M9.66M16.07M17.71M14.39M-18.24M25.58M7.13M10.56M-5.63M10.20M6.85M9.35M
Inventory --------------41.19M42.22M51.36M54.01M
Receivables --------------27.78M31.76M29.37M33.95M
Total Liabilities -----16.55M15.73M15.51M16.88M18.14M16.39M34.81M20.78M-52.03M52.85M86.26M86.78M
Current Liabilities --36.34M23.16M19.89M12.02M11.21M10.85M11.33M14.24M15.39M17.19M18.71M-28.91M23.73M29.29M37.33M
Long Term Debt -----------15.78M0-19.31M23.62M51.50M45.53M
Total Debt --------------21.31M25.62M54.25M49.65M
Total Equity 88.15M78.11M73.77M73.26M73.52M73.74M72.03M66.16M68.03M79.20M104.55M109.73M116.80M-116.28M125.33M134.00M130.00M
Shares Outstanding --------------20.57M20.78M21.07M21.09M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 2.03M10.91M10.96M4.77M6.90M3.67M8.55M7.65M7.27M10.89M-2.97M21.72M--1.26M1.93M16.64M10.99M
Investing Cash Flow -8.80M-1.95M-2.00M-812.00K-269.00K-1.39M-2.91M-11.08M-1.39M-4.18M-31.53M-2.98M--1.68M-2.55M-49.95M-3.87M
Financing Cash Flow 10.76M-10.63M-8.60M115.00K12.00K-751.00K-8.87M-175.00K1.40M1.17M16.12M-15.69M-518.00K5.49M29.86M-4.68M
Capital Expenditure -1.82M-1.76M-2.36M-2.69M-766.00K-1.65M-2.91M-1.22M-1.39M-4.18M-6.28M-3.10M--1.68M-2.55M-1.93M-3.87M
Free Cash Flow 212.00K9.15M8.60M2.08M6.13M2.01M5.64M6.43M5.88M6.70M-9.25M18.62M--2.94M-623.00K14.70M7.12M
Net Change in Cash --------------2.42M4.87M-3.46M2.44M
Share Buybacks 3.33M-----9.39M607.00K-742.00K1.96M0-----

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 22.9%28.0%25.2%28.3%28.7%29.1%30.5%30.4%30.7%29.3%29.2%27.1%-22.3%24.7%25.7%24.1%
Operating Margin % -2.3%7.1%1.8%-0.1%-0.8%-2.2%4.4%4.6%7.6%7.5%6.9%5.3%-0.1%6.0%6.1%3.3%
Net Margin % -6.0%-3.7%-1.5%-1.6%-1.2%-3.2%3.8%4.3%8.9%28.6%4.9%4.9%--0.1%4.5%3.8%-3.1%
ROE % -11.8%-8.4%-2.8%-2.2%-1.3%-2.9%4.3%5.2%9.7%23.8%4.7%4.5%--0.1%5.7%4.7%-4.5%
ROCE % -15.1%3.1%-0.1%-0.8%-1.9%4.7%5.1%7.8%6.2%5.8%4.8%-0.1%6.1%5.2%3.5%

Shareholding Pattern

Insiders
3.22%
Institutions
74.26%
Public Float
76.73%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ULBI

Yahoo Finance hu, 30 Jul 2026

Ultralife Corporation to Report Second Quarter Results on August 7, 2026

NEWARK, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its second quarter results for the period ended June 30, 2026, before the market opens on Friday, August 7, 2026. Ultralife’s Management will a…

Yahoo Finance hu, 16 Jul 2026

Zacks Initiates Coverage of Ultralife With Underperform Recommendation

Discover why Zacks rates Ultralife as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore ULBI's struggles with execution risks, margin pressure and commercialization delays that could delay its earning…

Yahoo Finance Mon, 01 Jun 2026

Ultralife (ULBI) Q1 2026 Earnings Transcript

Before turning the call over to management, I would like to remind everyone that some statements made during this conference call contain forward-looking statements based on current expectations. The company cautions investors not to place…

Yahoo Finance Fri, 22 May 2026

Undervalued Small Caps With Insider Buying Across Regions

The United States market has experienced a flat week, yet it has shown a robust 27% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of growth and stability, identifying sto…

Yahoo Finance ue, 12 May 2026

Undervalued Small Caps With Insider Activity To Consider In May 2026

Over the last 7 days, the United States market has risen by 2.6%, contributing to a significant 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this environment of robust growth, identifying small-cap stoc…

Yahoo Finance Sat, 09 May 2026

Ultralife Corp (ULBI) Q1 2026 Earnings Call Highlights: Record Backlog Amid Revenue Challenges

Despite a challenging quarter with revenue declines, Ultralife Corp (ULBI) focuses on strategic growth initiatives and reports a record backlog of $115.1 million.

ULBI — Frequently Asked Questions

What is the current share price of ULBI?

As of 2026-08-05 17:25 PDT, ULBI trades at $5.31 on NASDAQ/NYSE. Its 52-week range is $5.05 to $8.23.

What is the market capitalisation of ULBI?

ULBI has a market capitalisation of $112.00M on NASDAQ/NYSE.

What is the P/E ratio of ULBI?

ULBI trades at a trailing price-to-earnings (P/E) ratio of -15.17. Its price-to-book (P/B) ratio is 0.86.

What is the return on equity (ROE) of ULBI?

ULBI has a return on equity (ROE) of -4.54%. Its return on capital employed (ROCE) is 3.50%.

Is ULBI a good stock to buy?

This page provides a data-driven analysis of ULBI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space